Figure 5.
Pharmacological Inhibition of PI3Kδ Enhances the Anti-tumor Effects of i.v. Administered VVL15
(A and B) Tumor growth (A) and survival (B) of BALB/C mice bearing CT26 tumors treated with 75 mg/kg IC87114 or vehicle buffer 3 h prior to i.v. injection of 1 × 108 PFU of VVL15 (n = 10/group). Mice were treated three times, at the days indicated by arrows on the x axis. Day 0 represents the day of tumor cell inoculation into the animals. Data are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 (two-way ANOVA with Bonferonni multiple test correction). Survival analysis data are represented in a Kaplan-Meier plot and the significance (comparing VVL15 alone to IC87114 + VVL15) was assessed using the log-rank (Mantel-Cox) test. (C and D) Tumor growth (C) and survival (D) of BALB/c mice bearing orthotopic 4T1 tumors treated with 75 mg/kg IC87114 or PBS 3 h prior to i.v. injection of 1 × 108 PFU of VVL15 (n = 9/group). Mice were treated three times, at the days indicated by arrows on the x axis. Day 0 represents the day of tumor cell inoculation into the animals. Data are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 (two-way ANOVA with Bonferonni multiple test correction). Survival analysis data are represented in a Kaplan-Meier plot and the significance (comparing VVL15 alone to IC87114 + VVL15) was assessed using the log-rank (Mantel-Cox) test.